GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OTCPK:NEVPF) » Definitions » Cash Flow for Lease Financing

NEVPF (Abliva AB) Cash Flow for Lease Financing : $-0.04 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Abliva AB Cash Flow for Lease Financing?

Abliva AB's Cash Flow for Lease Financing for the three months ended in Sep. 2024 was $-0.01 Mil. Abliva AB's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.04 Mil.

Compared with last quarter ($-0.01 Mil in Jun. 2024 ), Abliva AB's Cash Flow for Lease Financing remained the same in Sep. 2024 ($-0.01 Mil).

Abliva AB Cash Flow for Lease Financing Historical Data

The historical data trend for Abliva AB's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB Cash Flow for Lease Financing Chart

Abliva AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.03 -0.01 -0.02 -0.03

Abliva AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Abliva AB Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abliva AB Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Abliva AB's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Abliva AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OTCPK:NEVPF) » Definitions » Cash Flow for Lease Financing
Comparable Companies
OSTO:ATORX XSAT:HAMLET B OSTO:BIOWKS OSTO:MAGLE OSTO:ACOU OSTO:KAN OSTO:ACTI OSTO:CLBIO OSTO:STABL OSTO:GUARD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ABLI:Sweden 0QDU:UK NTP:Germany
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Website
https://www.abliva.com
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.